RAPID-CPU: a prospective study on implementation of the ESC 0/1-hour algorithm and safety of discharge after rule-out of myocardial infarction.


Journal

European heart journal. Acute cardiovascular care
ISSN: 2048-8734
Titre abrégé: Eur Heart J Acute Cardiovasc Care
Pays: England
ID NLM: 101591369

Informations de publication

Date de publication:
Feb 2020
Historique:
pubmed: 13 7 2019
medline: 20 11 2020
entrez: 13 7 2019
Statut: ppublish

Résumé

Although the value of fast diagnostic protocols in suspected acute coronary syndrome has been validated, there is insufficient real world evidence including patients with lower pre-test probability, atypical symptoms and confounding comorbidities. The feasibility, efficacy and safety of European Society of Cardiology (ESC) 0/1 and 0/3-hour algorithms using high-sensitivity troponin T were evaluated in a consecutive cohort with suspected acute coronary syndrome. During 12 months, 2525 eligible patients were enrolled. In a pre-implementation period of 6 months, the prevalence of protocols, disposition, lengths of emergency department stay and treatments were registered. Implementation of the 0/1-hour protocol was monitored for another 6 months. Primary endpoints comprised the change of diagnostic protocols and 30-day mortality after direct discharge from the emergency department. Use of the ESC 0/1-hour algorithm increased by 270% at the cost of the standard 0/3-hour protocol. After rule-out (1588 patients), 1309 patients (76.1%) were discharged directly from the emergency department, with an all-cause mortality of 0.08% at 30 days (one death due to lung cancer). Median lengths of stay were 2.9 (1.9-3.8) and 3.2 (2.7-4.4) hours using a single high-sensitivity troponin T below the limit of detection (5 ng/L) at presentation and the ESC 0/1-hour algorithm, respectively, as compared to 5.3 (4.7-6.5) hours using the ESC 0/3-hour rule-out protocol ( Implementation of the ESC 0/1-hour algorithm is feasible and safe, is associated with shorter emergency department stay than the ESC 0/3-hour protocol, and an increase in discharge rates. ClinicalTrials.gov , Unique identifier: NCT03111862.

Sections du résumé

BACKGROUND BACKGROUND
Although the value of fast diagnostic protocols in suspected acute coronary syndrome has been validated, there is insufficient real world evidence including patients with lower pre-test probability, atypical symptoms and confounding comorbidities. The feasibility, efficacy and safety of European Society of Cardiology (ESC) 0/1 and 0/3-hour algorithms using high-sensitivity troponin T were evaluated in a consecutive cohort with suspected acute coronary syndrome.
METHODS METHODS
During 12 months, 2525 eligible patients were enrolled. In a pre-implementation period of 6 months, the prevalence of protocols, disposition, lengths of emergency department stay and treatments were registered. Implementation of the 0/1-hour protocol was monitored for another 6 months. Primary endpoints comprised the change of diagnostic protocols and 30-day mortality after direct discharge from the emergency department.
RESULTS RESULTS
Use of the ESC 0/1-hour algorithm increased by 270% at the cost of the standard 0/3-hour protocol. After rule-out (1588 patients), 1309 patients (76.1%) were discharged directly from the emergency department, with an all-cause mortality of 0.08% at 30 days (one death due to lung cancer). Median lengths of stay were 2.9 (1.9-3.8) and 3.2 (2.7-4.4) hours using a single high-sensitivity troponin T below the limit of detection (5 ng/L) at presentation and the ESC 0/1-hour algorithm, respectively, as compared to 5.3 (4.7-6.5) hours using the ESC 0/3-hour rule-out protocol (
CONCLUSION CONCLUSIONS
Implementation of the ESC 0/1-hour algorithm is feasible and safe, is associated with shorter emergency department stay than the ESC 0/3-hour protocol, and an increase in discharge rates.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov , Unique identifier: NCT03111862.

Identifiants

pubmed: 31298551
doi: 10.1177/2048872619861911
pmc: PMC7008552
doi:

Substances chimiques

Troponin T 0

Banques de données

ClinicalTrials.gov
['NCT03111862']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

39-51

Références

Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2):195-203
pubmed: 25737484
Int J Emerg Med. 2014 Oct 16;7:42
pubmed: 25635202
Ann Emerg Med. 2016 Jul;68(1):76-87.e4
pubmed: 26794254
JAMA Intern Med. 2014 Jan;174(1):51-8
pubmed: 24100783
J Am Coll Cardiol. 2016 Feb 9;67(5):502-11
pubmed: 26846948
Eur Heart J. 2015 Feb 21;36(8):464-7
pubmed: 25870872
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
Circulation. 2017 Apr 25;135(17):1586-1596
pubmed: 28034899
Circulation. 2018 Oct 16;138(16):1654-1665
pubmed: 30354460
Heart. 2014 Oct;100(20):1591-6
pubmed: 24947318
JAMA. 2015 Nov 10;314(18):1955-65
pubmed: 26547467
Ann Emerg Med. 2016 Jul;68(1):88-91
pubmed: 26875058
Circ Cardiovasc Qual Outcomes. 2016 Sep;9(5):542-53
pubmed: 27506926
J Am Coll Cardiol. 2018 Aug 7;72(6):620-632
pubmed: 30071991
J Am Coll Cardiol. 2016 Apr 5;67(13):1531-1540
pubmed: 27150684
Lancet. 2015 Dec 19;386(10012):2481-8
pubmed: 26454362
Int J Cardiol. 2017 Aug 1;240:1-7
pubmed: 28431769
Acute Card Care. 2012 Dec;14(4):131-7
pubmed: 23215748
N Engl J Med. 2000 Apr 20;342(16):1163-70
pubmed: 10770981
PLoS One. 2017 Nov 9;12(11):e0187662
pubmed: 29121105
Eur Heart J. 2016 Nov 21;37(44):3316-3323
pubmed: 28007934
Arch Intern Med. 2012 Sep 10;172(16):1211-8
pubmed: 22892889
Clin Chem. 2019 Mar;65(3):484-489
pubmed: 30626631
Ann Intern Med. 2017 May 16;166(10):715-724
pubmed: 28418520
Circulation. 2014 Dec 23;130(25):e344-426
pubmed: 25249585
Eur Heart J. 2016 Nov 21;37(44):3324-3332
pubmed: 27357358
Lancet. 2011 Mar 26;377(9771):1077-84
pubmed: 21435709
Ann Emerg Med. 2016 Jul;68(1):93-102.e1
pubmed: 26947800
Emerg Med J. 2017 Jun;34(6):349-356
pubmed: 27565197
BMJ. 2011 Jun 01;342:d2983
pubmed: 21632665
Emerg Med Australas. 2016 Aug;28(4):383-90
pubmed: 27250806
Eur Heart J. 2012 Oct;33(20):2551-67
pubmed: 22922414
Heart. 2018 Oct;104(20):1714-1722
pubmed: 29724751
BMJ. 2006 Nov 25;333(7578):1091
pubmed: 17032691
Eur Heart J. 2015 Feb 7;36(6):369-76
pubmed: 24786301
J Am Coll Cardiol. 2013 Oct 1;62(14):1242-1249
pubmed: 23583250
Circulation. 2018 Jan 23;137(4):354-363
pubmed: 29138293
Health Technol Assess. 2015 Jun;19(44):1-234
pubmed: 26118801
JAMA Cardiol. 2016 Jul 1;1(4):397-404
pubmed: 27438315
CMAJ. 2015 May 19;187(8):E243-E252
pubmed: 25869867
PLoS One. 2018 Aug 23;13(8):e0202133
pubmed: 30138394
BMJ Open. 2016 Feb 25;6(2):e009746
pubmed: 26916691
Int J Cardiol. 2013 Jul 1;166(3):752-4
pubmed: 23084108

Auteurs

Kiril M Stoyanov (KM)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Hauke Hund (H)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.
Faculty of Informatics, Heilbronn University of Applied Sciences, Germany.

Moritz Biener (M)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Jochen Gandowitz (J)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Christoph Riedle (C)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Julia Löhr (J)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Matthias Mueller-Hennessen (M)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Mehrshad Vafaie (M)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Hugo A Katus (HA)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Evangelos Giannitsis (E)

Department of Cardiology, Angiology and Pulmonology, Heidelberg University Hospital, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH